|
|
|
|
| LEADER |
01000cam a22002652 4500 |
| 001 |
1657336212 |
| 003 |
DE-627 |
| 005 |
20230428190947.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
150703s2015 gw |||||o 00| ||eng c |
| 020 |
|
|
|a 9783319141510
|9 978-3-319-14151-0
|
| 024 |
7 |
|
|a 10.1007/978-3-319-14151-0
|2 doi
|
| 035 |
|
|
|a (DE-627)1657336212
|
| 035 |
|
|
|a (DE-576)434884200
|
| 035 |
|
|
|a (DE-599)BSZ434884200
|
| 035 |
|
|
|a (OCoLC)985114806
|
| 035 |
|
|
|a (DE-He213)978-3-319-14151-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 044 |
|
|
|c XA-DE
|
| 050 |
|
0 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 084 |
|
|
|a VS 9100
|q SEPA
|2 rvk
|0 (DE-625)rvk/147725:253
|
| 245 |
1 |
0 |
|a PARP Inhibitors for Cancer Therapy
|c edited by Nicola J. Curtin, Ricky A. Sharma
|
| 264 |
|
1 |
|a [s.l.]
|b Humana Press
|c 2015
|
| 300 |
|
|
|a Online-Ressource (XIX, 591 p. 108 illus., 85 illus. in color, online resource)
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Cancer Drug Discovery and Development
|v 83
|
| 490 |
0 |
|
|a SpringerLink
|a Bücher
|
| 500 |
|
|
|a Description based upon print version of record
|
| 505 |
8 |
0 |
|a History of the discovery of poly (ADP-ribose)Discovery of the PARP superfamily and focus on the lesser exhibited but not lesser talented members -- The role of PARPs in DNA Strand Break Repair -- TIPs: Tankyrase Interacting Proteins -- PARP and Carcinogenesis -- Multitasking roles for poly(ADP-ribosyl)ation in aging and longevity -- Overview of PARP Inhibitor Design and Optimization -- Structure Based Design of PARP Inhibitors -- Preclinical chemosensitization by PARP inhibitors -- Classification of PARP inhibitors based on PARP trapping and catalytic inhibition, and rationale for combinations with topoisomerase I inhibitors and alkylating agents -- Radiosensitisation by poly(ADP-ribose) polymerase inhibition -- The vasoactivity of PARP inhibitors -- Synthetic lethality with Homologous Recombination Repair defects -- Targeting tumour hypoxia with PARP Inhibitors: Contextual synthetic lethality -- Other determinants of sensitivity -- Synthetic sickness with molecularly targeted agents against the EGFR pathway -- Disruption of DNA repair by cell cycle and transcriptional CDK inhibition -- Resistance to PARP Inhibitors Mediated by Secondary BRCA1/2 Mutations -- PARP inhibitor resistance - what is beyond BRCA1 or BRCA2 restoration -- Introduction to PARPi clinical trials and future directions -- Clinical trials investigating PARP inhibitors as single agents -- Clinical trials of PARP inhibitors with chemotherapy -- Combination of PARP inhibitors with clinical radiotherapy -- Biomarkers for PARP Inhibitors.
|
| 520 |
|
|
|a PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP-poly ADP ribose polymerase-in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors. PARP inhibitors-PARPi-are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The “synthetic lethality” of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area
|
| 650 |
|
0 |
|a Medicine
|
| 650 |
|
0 |
|a Oncology
|
| 650 |
|
0 |
|a Drug interactions
|
| 650 |
|
0 |
|a Biomedicine
|
| 650 |
|
0 |
|a Medicine
|
| 650 |
|
0 |
|a Oncology
|
| 650 |
|
0 |
|a Drug interactions
|
| 700 |
1 |
|
|a Curtin, Nicola J.
|e hrsg
|4 edt
|
| 700 |
1 |
|
|a Sharma, Ricky A.
|e hrsg
|4 edt
|
| 776 |
1 |
|
|z 9783319141503
|
| 776 |
0 |
8 |
|i Druckausg.
|t PARP inhibitors for cancer therapy
|d [S.l.] : Humana Press, 2015
|h XIII, 591 S.
|w (DE-627)1616110708
|w (DE-576)443643814
|z 9783319141503
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-319-14151-0
|x Verlag
|3 Volltext
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-14151-0
|x Resolving-System
|3 Volltext
|
| 856 |
4 |
2 |
|u https://swbplus.bsz-bw.de/bsz434884200cov.jpg
|m V:DE-576
|m X:springer
|q image/jpeg
|v 20150811143923
|3 Cover
|
| 889 |
|
|
|w (DE-627)829641645
|
| 912 |
|
|
|a ZDB-2-SME
|b 2015
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a ISIL_DE-18
|
| 912 |
|
|
|a SYSFLAG_1
|
| 912 |
|
|
|a GBV_KXP
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a GBV_ILN_22_i06404
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a ISIL_DE-715
|
| 912 |
|
|
|a GBV_ILN_2017
|
| 912 |
|
|
|a ISIL_DE-576
|
| 935 |
|
|
|h GBV
|i ExPruef
|
| 936 |
r |
v |
|a VS 9100
|b Allgemeines
|k Chemie und Pharmazie
|k Pharmazeutische Chemie und Molekularpharmakologie
|k Einzelne Arzneimittel- und Wirkstoffgruppen
|k Tumor: Arzneimittel und Therapie
|k Allgemeines
|0 (DE-627)1271713802
|0 (DE-625)rvk/147725:253
|0 (DE-576)201713802
|
| 951 |
|
|
|a BO
|
| 953 |
|
|
|2 045F
|a 614.5999
|
| 980 |
|
|
|2 22
|1 01
|x 0018
|b 1553094859
|c 00
|f --%%--
|d --%%--
|e s
|j --%%--
|k Campuslizenz Universität Hamburg. - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.
|y zi06404
|z 14-07-15
|
| 980 |
|
|
|2 120
|1 01
|x 0715
|b 1776343123
|h OLR-ESP
|k Campusweiter Zugriff (Universität Oldenburg). - Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden.
|y z
|z 08-06-18
|
| 980 |
|
|
|2 120
|1 02
|x 0715
|b 3581104911
|c 00
|f --%%--
|d --%%--
|e g
|j --%%--
|h alma
|k ww
|y z
|z 24-01-20
|
| 980 |
|
|
|2 2017
|1 01
|x DE-576
|b 3395501442
|c 00
|f --%%--
|d --%%--
|e --%%--
|j n
|k Besitznachweis BSZ nur für Dateneinspielung, keine echte Lizenz vorhanden
|y l01
|z 13-06-15
|
| 981 |
|
|
|2 22
|1 01
|x 0018
|y Volltextzugang
|r https://doi.org/10.1007/978-3-319-14151-0
|
| 981 |
|
|
|2 22
|1 01
|x 0018
|y Nur für Angehörige der Universität Hamburg: Volltextzugang von außerhalb des Campus
|r http://emedien.sub.uni-hamburg.de/han/SpringerEbooksUKE/doi.org/10.1007/978-3-319-14151-0
|
| 981 |
|
|
|2 120
|1 01
|x 0715
|r http://dx.doi.org/10.1007/978-3-319-14151-0
|
| 981 |
|
|
|2 120
|1 02
|x 0715
|r http://49gbv-uob-primo.hosted.exlibrisgroup.com/openurl/49GBV_UOB/UOB_services_page?u.ignore_date_coverage=true&rft.mms_id=991016133113503501
|
| 983 |
|
|
|2 120
|1 00
|x DE-715
|8 99
|a ww
|
| 985 |
|
|
|2 22
|1 01
|x 0018
|a h64 ebook
|
| 985 |
|
|
|2 120
|1 01
|x 0715
|a YH 2021
|
| 995 |
|
|
|2 120
|1 01
|x 0715
|a OLR-ESP
|
| 995 |
|
|
|2 120
|1 02
|x 0715
|a alma
|
